Tin tức & Cập nhật

Abrocitinib effectively controls AD regardless of dosing regimen
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023 bởiAudrey Abella

In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.

Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023